Donini P, Montezezemol R. Rassegna di clinica, terapia scieze affini (a publication of the Biologic Laboratories of the Instituto Serono). 1949;48(143):3–28.

Lunenfeld B, Sulimovici S, Ranau E, Eshkol A. L’induction de l’ovulation dans les aménorrhées hypophysaires par un traitement combiné de gonadotrophines urinaires ménopausiques et de gonadotrophine chorionique. CR Soc Franc Gynecol. 1962;32:346–51.

Cook AS, Webster BW, Terranova PF, Keel BA. Variation in the biologic and biochemical characteristics of human menopausal gonadotropin. Fertil Steril. 1988;49(4):704–12.PubMed

Howles CM, Loumaye E, Giroud D, Luyet G. Multiple follicular development and ovarian steroidogenesis following subcutaneous administration of a highly purified urinary FSH preparation in pituitary desensitized women undergoing IVF: a multicentre European phase III study. Hum Reprod. 1994;9(3):424–30.PubMed

Giudice E, Crisci C, Eshkol A, Papoian R. Composition of commercial gonadotropin preparation extracted from human post-menopausal urine: characterization of non-gonadotropin proteins. Hum Reprod. 1994;9(12):2291–9.PubMed

Li TC, Hindle JE. Adverse local reaction to intramuscular injection of urinary-derived gonadotropins. Hum Reprod. 1993;8(11):1835–6.PubMed

Al-Inany HG, Abou-Setta AM, Aboulghar MA, Mansour RT, Serour GI. Highly purified hMG achieves better pregnancy rates in IVF cycle but not ICSI cycles compared with recombinant FSH: a meta-analysis. Gynecol Endocrinol. 2009;25(6):372–8.CrossRefPubMed

Schoemaker J, Wentz AC, Jones GS, Dubin NH, Sapp KC. Stimulation of follicular growth with “pure” FSH in patients with anovulation and elevated LH levels. Obstet Gynecol. 1978;51(3):270–7.CrossRefPubMed

Bouloux PM, Handelsman DJ, Jockenhövel F, Nieschlag E, Rabinovici J, Frasa WL, et al.; FSH-CTP study group. First human exposure to FSH-CPT in hypogonadotrophic hypogonadal males. Hum Reprod. 2001;16(8):1592–7.

Duijkers IJ, Klipping C, Boerrigter PJ, Machielsen CS, De Bie JJ, Voortman G. Single dose pharmacokinetics and serum hormones of a long acting recombinant FSH preparation (FSH-CTP) in healthy pituitary subpressed females. Hum Reprod. 2002;17(8):1987–93.CrossRefPubMed

Beckers NG, Macklon NS, Devroey P, Platteau P, Boerrigter PJ, Fauser BC. First live birth after ovarian stimulation using a chimeric long acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for in vitro fertilization. Fertil Steril. 2003;79(3):621–3.CrossRefPubMed

Corifollitropin alfa Ensure Study Group. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower-body-weight women. Reprod Biomed Online. 2010;21(1):66–76.CrossRef

Devroey P, Boostanfar R, Koper NP, Mannaerts BM, Ijzerman-Boon PC, Fauser BC; ENGAGE Investigators. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod. 2009;24(12):3063–72.

Santjohanser C, Schultze-Mosgau A. Letter to the editor on the article “Long-acting-FSH (FSH-CTP) in reproductive medicine”. Gynakol Endocrinol. 2009;7(3):183.

Shoham Z, Zosmer A, Insler V. Early miscarriage and fetal malformations after induction of ovulation (by clomiphene citrate and/or human menotropins), in vitro fertilization, and gamete intrafallopian transfer. Fertil Steril. 1991;55(1):1–11.PubMed